Human interferon .tau. proteins and methods of use

• US 5,738,845 A
• Filed: 05/31/1995
• Issued: 04/14/1998
• Est. Priority Date: 03/02/1989
• Status: Expired due to Fees

• Current Assignee: University of Florida (State University System of Florida), The Women's Research Institute
• Original Assignee: The Women's Research Institute
• Inventors: Imakawa, Kazuhiko
• Primary Examiner(s): Fitzgerald, David L.
• Application Number:
  US08/443,883
• Time in Patent Office: 1,049 Days
• Field of Search: 530/351, 435/69.52, 424/85.4
• US Class Current: 424/85.4
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: C07K 14/555 Interferons [IFN]
• CPC Class Codes: C07K 14/56 IFN-alpha
• CPC Class Codes: C07K 16/249 Interferons
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/02 containing a signal sequence

Abstract

The present invention describes the production of interferon-τ proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-τ protein are also described. In one aspect, the invention includes ovine interferon-τ. In another aspect the invention includes multiple forms of human interferon-τ.

Claims

1. An isolated human interferon-τ

protein comprising an amino acid sequence encoded by a nucleic acid molecule present in a human DNA library, wherein the coding sequence of said nucleic acid molecule exhibits at least 95% identity to the coding sequence set forth in SEO ID NO;

43, 29, 33, 25, 27, 21, or 23.

2. A protein of claim 1, where said protein is recombinantly produced.

3. A method of inhibiting the growth of tumor cells, comprising the step of contacting the tumor cells with a human interferon-τ

protein according to claim 1 at a concentration effective to inhibit their growth.

4. A method according to claim 3, wherein the tumor cells are human carcinoma cells, human leukemia cells, human T-lymphoma cells, or human melanoma cells.

5. A methods according to claim 4, wherein the tumor cells are steroid-sensitive.

6. A method according to claim 5, wherein the tumor cells are mammary tumor cells.

7. A method of inhibiting the replication of a virus within cells infected by the virus, comprising the step of contacting the infected cells with a human interferon-τ

protein according to claim 1 at a concentration effective to inhibit the replication of the virus within the cells.

8. A method according to claim 7, wherein the virus is an RNA virus.

9. A method according to claim 8, wherein the virus is a human immunodeficiency virus or hepatitis C virus.

10. A method according to claim 7, wherein the virus is a DNA virus.

11. A method according to claim 10, wherein the virus is hepatitis B virus.

12. An isolated interferon-τ

protein comprising the amino acid sequence presented as SEQ ID NO;

44.

13. An isolated interferon-τ

protein comprising the amino acid sequence presented as SEQ ID NO;

30, wherein Xaa represents any amine acid.

14. An isolated interferon-τ

protein comprising the amino acid sequence presented as SEQ ID NO;

34.

15. An isolated interferon-τ

protein comprising the amino acid sequence presented as SEQ ID NO;

26.

16. An isolated interferon-τ

protein comprising the amino acid sequence presented as SEQ ID NO;

28.

17. An isolated interferon-τ

protein comprising the amino acid sequence presented as SEQ ID NO;

22.

18. An solated interferon-τ

proten comprising the amino acid sequence presented as SEQ ID NO;

24.